within Pharmacolibrary.Drugs.ATC.C;

model C04AE04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 0.0003333333333333333,
    adminDuration  = 600,
    adminMass      = 6 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.25,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C04AE04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Dihydroergocristine is a semisynthetic ergot alkaloid, part of the ergoloid mesylates group. It has vasodilatory and nootropic effects and has historically been used to manage cognitive and vascular disorders, including dementia and peripheral vascular disease. It is not widely approved in current clinical practice in many countries due to limited recent use, but may still be available in some regions.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for a typical adult population after oral administration, as published data with detailed pharmacokinetics for dihydroergocristine alone are lacking.</p><h4>References</h4><ol><li><p>Coppi, G, et al., &amp; Mailland, F (1992). [The pharmacokinetics of dihydroergocristine in free-will subjects after oral administration of three formulations]. <i>Arzneimittel-Forschung</i> 42(11A) 1397–1399. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1492860/\">https://pubmed.ncbi.nlm.nih.gov/1492860</a></p></li><li><p>Grognet, JM, et al., &amp; Coppi, G (1992). [The pharmacokinetics of dihydroergocristine after intravenous and oral administration in rats]. <i>Arzneimittel-Forschung</i> 42(11A) 1394–1396. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1492859/\">https://pubmed.ncbi.nlm.nih.gov/1492859</a></p></li><li><p>Bicalho, B, et al., &amp; De Nucci, G (2008). Identification and human pharmacokinetics of dihydroergotoxine metabolites in man: preliminary results. <i>Biopharmaceutics &amp; drug disposition</i> 29(1) 17–28. DOI:<a href=\"https://doi.org/10.1002/bdd.585\">10.1002/bdd.585</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17941060/\">https://pubmed.ncbi.nlm.nih.gov/17941060</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C04AE04;
